2014 FDA Healthcare Provider Side effects 
Pharmaceutical Technology
NOVEMBER 30, 2022
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years.
Pharmaceutical Technology
NOVEMBER 30, 2022
In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years.
Expert insights. Personalized for you.
105 
Let's personalize your content